secwatch.observer — SEC 8-K summary
======================================

Issuer:     Astria Therapeutics, Inc. (—)
CIK:        0001454789
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001104659-26-006228
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 2.01, 2.03, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Astria Therapeutics acquired by BioCryst; stockholders receive 0.59 shares + $8.55 cash per share
--------------------------------------------------------------------------------

- Merger closed: each Astria share converted into 0.59 BioCryst share plus $8.55 cash.
- BioCryst financed cash portion with ~$396.6M net term loans and issued ~37.3M shares.
- Astria common stock delisted from Nasdaq; trading suspended Jan 23, 2026.
- All former directors and executive officers resigned; new directors appointed including Babar Ghias as President.
- Loan Agreement provides $400M term loans, maturing Jan 23, 2031, with customary covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1454789/000110465926006228/0001104659-26-006228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1454789/000110465926006228/tm263900d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-006228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer